As AI moves from pilot to operational reality, a big, looming question is taking over: How do you govern it?
That question carries a lot of weight in healthcare, especially for LTC pharmacies. AI is now touching clinical decisions. Orders are being processed without a human keying every field. And regulators, at both state and federal levels, are paying close attention to what pharmacies can actually demonstrate about how their AI behaves.
Getting governance right is not just a compliance exercise. It is what makes AI in pharmacy sustainable.
In Healthcare, innovation often precedes regulatory shifts. As new innovations are implemented, this is a clear leading indicator that regulations are ensuing to ensure clinical efficacy and equity across patient populations. In some cases, regulations can lag behind new innovations anywhere from a few months to a few years. When it comes to AI, innovation is accelerating rapidly with large shifts happening in real-time. With these developments, AI governance in healthcare has moved from theory to an operational requirement quickly. By mid-2025, more than 250 AI-focused healthcare bills had been introduced across 34+ states. States such as Colorado, Utah, and California are already advancing legislation focused on transparency, accountability, and data privacy.
Colorado's AI legislation is one to watch closely. The Colorado AI Policy Work Group is moving to revise SB 205 before it takes effect on June 30, 2026, with healthcare entities facing specific disclosure and oversight requirements for AI systems that touch clinical decisions.
At the federal level, the FDA's January 2025 guidance introduced a Total Product Life Cycle approach for AI-enabled systems. This requires clear documentation of model design, data lineage, validation processes, bias monitoring, and ongoing performance tracking. At the same time, updates to the FDA's Quality Management System Regulation in 2026 will further tighten expectations around what "validated" means in real-world clinical environments.
For LTC pharmacies, an approach that allows pharmacies to invest in AI in a way that is implemented with future compliance in mind the future is straightforward: AI systems must be documented, auditable, and configurable. The question is no longer whether these standards are coming. It is whether current systems are built to meet them when they do arrive.
Many automation tools used in pharmacy today rely on screen scraping, browser overlays, auto-clickers, or external bots. While these technologies can reduce manual effort and improve efficiency, they can also introduce a serious governance and compliance challenge.
When AI bots and automations take action outside the pharmacy system of record, the activity is often not fully captured within the workflow itself. This creates gaps in visibility around how decisions were made, when actions occurred, and whether a human user or an AI-driven process initiated the activity.
In long-term care pharmacy, this level of traceability matters. Pharmacies process thousands of prescriptions every year and are responsible for maintaining a complete and defensible record of the medication journey from order entry to dispensing to administration. During an audit, investigation, or adverse event review, organizations may need to quickly reconstruct:
As federal, state, and CMS oversight around AI governance continues to evolve, pharmacies will face increasing pressure to demonstrate not only what decisions were made, but also how those decisions were reached.
If AI activity occurs outside the core workflow, reporting can become fragmented and difficult to defend. Reconstructing timelines across disconnected systems or third-party automation tools can slow investigations, complicate audits, and create unnecessary compliance risk. Systems that cannot be closely monitored, validated, and audited should raise concern for organizations ultimately responsible for patient safety and clinical efficacy.
The result:
The Joint Commission and Coalition for Health A have made expectations clear: healthcare organizations must maintain full documentation of AI decisions, validation processes, monitoring activity, and adverse event investigations. An AI tool that operates outside the pharmacy system cannot meet that standard.
The FDA's AI guidance reinforces the need for ALCOA+ principles: data and system activity must be Attributable, Traceable, Accurate, and Consistently Available.
In practice, that translates into a few non-negotiables:
✔ Every AI action must be logged at the field level
✔ Decision pathways must be visible and reviewable
✔ Workflow changes must be tracked continuously
✔ Automation must be configurable based on clinical risk
Controlled substances are the clearest example. Regulatory frameworks already require stricter controls, auditability, and documented workflows for higher-risk medications, and state-level laws such as SB 205 are reinforcing these expectations through mandated risk management, impact assessments, and ongoing monitoring of AI-driven decisions.
Real-time visibility is also becoming an expectation rather than a feature. Guidance and evolving requirements from Centers for Medicare & Medicaid Services (CMS) increasingly emphasize timely access to documentation, audit trails, and transaction data across clinical and dispensing workflows.
This is where native AI and overlay automation diverge most clearly.
FrameworkLTC+™ operates directly inside the FrameworkLTC platform. It does not sit on top of the system as a separate layer. Every action taken by the AI is captured within the same environment used for clinical and operational workflows.
That includes:
✔ Full field-level audit history on every AI-processed order
✔ Continuous, real-time activity tracking built into the workflow
✔ Visual indicators identifying AI-touched orders throughout order entry screens and grids
✔ Embedded workflow visibility during pharmacist verification
The audit trail is not something generated after the fact. It exists as a continuous record inside the system, exactly where reviewers and regulators will look for it.
Beyond visibility, the platform gives pharmacies direct operational control:
✔ Adjustable automation levels based on volume, staffing, and readiness
✔ Configurable handling rules for controlled substances, including mandatory human review for higher-risk medications
✔ Ability to scale or pause automation as operational needs shift
SoftWriters' internal regulatory compliance team monitors state and federal developments weekly, sharing findings with customers monthly, so pharmacies are not left tracking an evolving regulatory landscape alone.
AI governance is not just about compliance. It directly impacts operations and financial exposure.
Pharmacies with audit-ready systems are better positioned to respond to regulatory reviews, answer facility-level questions about how resident medications are processed, and maintain internal confidence in automation. As 46% of U.S. healthcare organizations adopt generative AI, governance is becoming a differentiator between pharmacies that scale confidently and those that accumulate compliance risk quietly. For LTC pharmacies already operating on compressed margins, that is not a cost that appears on the roadmap until it is unavoidable.
The direction across state laws, FDA guidance, and CMS expectations is converging on three principles: Transparency, Explainability and Auditability.
FrameworkLTC+™ was designed with all three in mind, not as future requirements to prepare for, but as current operational needs that pharmacy AI must meet today.
With electronic prescribing of controlled substances expected to become mandatory by January 1, 2028, and real-time audit log expectations likely to follow, pharmacies have a defined window to build governance infrastructure before it becomes a condition of participation rather than a best practice.
The pharmacies that use that window effectively will move into AI-enabled operations more confidently and on their own terms.